Healthcare Industry News: enzyme replacement therapy
News Release - April 27, 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, InternationalIndustry Veteran With Extensive International Commercial Experience
Former SVP, Europe & Canada at Biogen
CRANBURY, N.J., April 27, 2015 -- (Healthcare Sales & Marketing Network) -- Amicus Therapeutics (FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has appointed David Allsop as Senior Vice President, International, effective today. He will be responsible for Amicus' international organizational build out, and will lead international commercial and market access activities for migalastat monotherapy for Fabry disease. Mr. Allsop will serve as a member of the Amicus executive team reporting to Bradley L. Campbell, President and Chief Operating Officer.
Mr. Allsop brings over 27 years of international General Management and commercial experience in the biopharmaceutical industry between Biogen Idec and Janssen-Cilag, with extensive operational and strategic leadership in the areas of neurology, autoimmune diseases, hemophilia, gastroenterology, dermatology, and renal. He has successfully launched three blockbuster therapies internationally as well as many other therapies both nationally and internationally. Mr. Allsop has both direct and indirect experience in securing market access and reimbursement in the European Union and international markets.
"I am very pleased to welcome David to our executive team," stated Mr. Campbell. "His high level of international experience at top-tier biopharmaceutical companies will be extremely valuable as we build the Amicus team in preparation for the global launch of migalastat monotherapy for Fabry disease. I am confident that under David's leadership, Amicus can establish a prominent presence in Europe first, followed by other key global markets, and attract top talent to our international organization as a key part of our vision to build a leading global biotechnology company focused on developing and commercializing transformational treatments for people living with devastating rare diseases."
Prior to joining Amicus, Mr. Allsop was instrumental in building Biogen's international commercial organization over the last 17 years. He most recently served as Senior Vice President, Europe and Canada, with full responsibility for the business and organization in those territories. While at Biogen he led the successful international launch of several products in the multiple sclerosis franchise, including Avonex(R), Tysabri(R), Fampyra(R), Tecfidera(R) and Plegridy(TM) as well as taking responsibility for the hemophilia development organization. Prior to his tenure at Biogen, Mr. Allsop spent 10 years in roles of increasing responsibility at Janssen-Cilag, working in gastroenterology, dermatology and renal, including building and running a number of commercial units and taking responsibility for the Company's largest brand in the United Kingdom.
"I am absolutely thrilled and excited to be joining such a wonderful company at such an important time," said Mr. Allsop. "I have been very lucky in my career to be involved with companies that put the welfare of patients at the heart of their mission and Amicus has a focus on helping the people suffering from lysosomal storage disorders which is incredibly impressive. Through its global clinical operations, medical affairs and patient advocacy, Amicus has already established a strong reputation with the international Fabry community that I believe will provide a solid foundation for the migalastat launch. I look forward to hiring great people who want to make a difference and quickly building out the European organization and then establishing an international footprint for Amicus across rare diseases."
About Amicus Therapeutics
Amicus Therapeutics (FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and MPS-1.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus' candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products and the projected cash position for the Company. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "potential," "plan," "targets," "likely," "may," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2014. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Source: Amicus Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.